Immunomodulatory proteins, such as programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4), can be therapeutic targets for T1D. The gene discussed is CD274; the disease is type 1 diabetes mellitus.